Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Dr David Stamler’s Biotech Showcase Presentation

January 7, 2019 Kerry Rowe

Prana Biotechnology BSC Presntation 20180107 FINAL

Post navigation

Prana Presents at Biotech Showcase

Prana receives Orphan Designation for PBT434 for treatment of MSA

Related Posts

Prana Receives Approval For 12-Month Open Label Extension Study In Alzheimer’s Disease

July 17, 2013May 5, 2019

Quarterly Cash Flow Report

January 29, 2021May 19, 2021

AGM Presentation

November 12, 2015

Recent Posts

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065